Home > Journals > Esperienze Dermatologiche > Past Issues > Esperienze Dermatologiche 2019 December;21(2-4) > Esperienze Dermatologiche 2019 December;21(2-4):39-41

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

Esperienze Dermatologiche 2019 December;21(2-4):39-41

DOI: 10.23736/S1128-9155.19.00493-X

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Drugs in HIV patients: our experience

Caterina MAZZELLA 1 , Tiziana PEDUTO 1, Gabriella FABBROCINI 1, Giovanni DI FILIPPO 2, Francesco BORRELLI 2, Mariarosaria COTUGNO 2, Maria GUARINO 1, Maria A. LUCIANO 3, Mario DELFINO 1

1 Unit of Dermatology, Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy; 2 Section of Infectious Diseases, Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy; 3 Unit of Dermatology, Department of Public Health, Federico II University, Naples, Italy


PDF


BACKGROUND: Highly active antiretroviral therapy (HAART) has modified the expectation and quality of life of HIV-infected individuals. Increased survival of these patients has created the problem of comorbidities and an increase in cutaneous drug reactions.
METHODS: We administered a questionnaire to five HIV-centers in Campania to extract epidemiologic profile and data about comorbidities and on drug cutaneous reactions in the HAART- era.
RESULTS: Data of five centers were very similar to each other: 40% of patients had 35- 50 years, 15% were alcohol-dependent, 10% were toxic-dependent, 66% of patients were males versus 34% of women. The most frequent sexual infection was syphilis, 40% of patients were affected from HCV and HBV, 80% of patients were subjected to the vaccine influenza virus vaccine without adverse reactions, the most common comorbidities were cardiovascular disease and metabolic bone diseases. Ten of percent of patients developed adverse drug reactions for comorbidities therapy, while 20% had skin reactions to antiretroviral therapy.
CONCLUSIONS: Active collaboration between the infectious diseases specialists and dermatologists is important to study HAART adverse skin reactions and increasing the adherence to treatment.


KEY WORDS: HIV; Drug-related side effects and adverse reactions; Inflammation

top of page